CBP501

CBP501 is a G2 checkpoint inhibitor peptide that abrogates the cell cycle arrest by targeting kinases like MAPKAP-K2 and CHK1, which regulate Cdc25C. This inhibition prevents Cdc2/cyclin B activation, blocking mitotic entry. It has been utilized in preclinical cancer research, showing potential to enhance chemotherapy efficacy in both in vitro and in vivo models.

Product Specifications

CAS Number

565434-85-7

Field of Research

Neuroscience

Smiles

C ([C@H] (C (N[C@@H] (C (N[C@H] (CC1=C (F) C (F) =C (F) C (F) =C1F) C (N[C@H] (CC2CCCCC2) C (N[C@@H] (C (N[C@@H] (C (N[C@@H] (C (N[C@@H] (C (N[C@@H] (C (N[C@H] (CCCNC (=N) N) C (O) =O) =O) CCCNC (=N) N) =O) CCC (N) =O) =O) CCCNC (=N) N) =O) CCCNC (=N) N) =O) CCCNC (=N) N) =O) =O) =O) CO) =O) NC ([C@H] (NC ([C@@H] (CC3=CC=C (C (=O) C4=CC=CC=C4) C=C3) N) =O) CO) =O) C=5C=6C (NC5) =CC=CC6